Literature DB >> 35169054

Perifollicular Hypopigmentation in Systemic Sclerosis: Associations With Clinical Features and Internal Organ Involvement.

Melody P Chung1, Christopher A Mecoli1, Jamie Perin2, Carrie Richardson3, Zsuzsanna H McMahan1.   

Abstract

OBJECTIVE: To determine whether perifollicular hypopigmentation in systemic sclerosis (SSc) is associated with demographics, distinct clinical features, and autoantibody profiles.
METHODS: Patients with SSc were prospectively enrolled, with a standardized data form used to collect anatomic distribution of perifollicular hypopigmentation. Associations between hypopigmentation and features of SSc were assessed.
RESULTS: Of 179 adult patients with SSc, 36 (20%) patients had perifollicular hypopigmentation. Of these 36 patients, 94% (n = 34) were female and 33% (n = 12) had limited cutaneous SSc. In univariable logistic regression, Black race (odds ratio [OR] 15.63, 95% CI 6.6-37.20, P < 0.001), diffuse cutaneous SSc (dcSSc; OR 4.62, 95% CI 2.11-10.09, P < 0.001), higher maximum modified Rodnan skin score (mRSS; OR 1.05, 95% CI 1.02-1.08, P = 0.003), myopathy (OR 3.92, 95% CI 1.80-8.57, P < 0.001), pulmonary fibrosis (OR 2.69, 95% CI 1.20-6.02, P = 0.02), lower minimum forced vital capacity % predicted (OR 0.96, 95% CI 0.94-0.99, P = 0.001), and lower minimum diffusing capacity for carbon monoxide % predicted (OR 0.97, 95% CI 0.95-0.99, P = 0.009) were associated with hypopigmentation. Anticentromere antibodies inversely associated with hypopigmentation (OR 0.24, 95% CI 0.07-0.86, P = 0.03). After adjusting for age, race, and disease duration, dcSSc (OR 4.28, 95% CI 1.46-12.53, P = 0.008) and increased mRSS (OR 1.07, 95% CI 1.02-1.12, P = 0.009) were significantly associated with hypopigmentation.
CONCLUSION: Perifollicular hypopigmentation is observed in a subset of patients with SSc and associated with diffuse subtype. Larger prospective studies determining whether perifollicular hypopigmentation precedes end-organ involvement and whether specific patterns associate with internal organ involvement are needed.
Copyright © 2022 The Journal of Rheumatology.

Entities:  

Keywords:  hypopigmentation; perifollicular; pigmentation; scleroderma; systemic sclerosis

Mesh:

Year:  2022        PMID: 35169054      PMCID: PMC9064889          DOI: 10.3899/jrheum.210983

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   5.346


  10 in total

Review 1.  Assessment of disease severity and prognosis.

Authors:  T A Medsger; S Bombardieri; L Czirjak; R Scorza; A Della Rossa; W Bencivelli
Journal:  Clin Exp Rheumatol       Date:  2003       Impact factor: 4.473

2.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2016-02

3.  Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis.

Authors:  Kamal K Solanki; Cecil Hor; Winston S J Chang; Christopher Frampton; Douglas H N White
Journal:  Int J Rheum Dis       Date:  2017-03-06       Impact factor: 2.454

4.  Profile of systemic sclerosis in a tertiary care center in North India.

Authors:  Vinod K Sharma; Tejasvi Trilokraj; Binod K Khaitan; Sumanth M Krishna
Journal:  Indian J Dermatol Venereol Leprol       Date:  2006 Nov-Dec       Impact factor: 2.545

5.  Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patients.

Authors:  Vaianu Leroy; Pauline Henrot; Thomas Barnetche; Muriel Cario; Anne-Sophie Darrigade; Pauline Manicki; Marie-Sylvie Doutre; Estibaliz Lazaro; Joel Constans; Damien Barcat; Jean-Philippe Vernhes; Christophe Richez; Alain Taieb; Marie-Elise Truchetet; Julien Seneschal
Journal:  J Am Acad Dermatol       Date:  2018-08-07       Impact factor: 11.527

6.  The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.

Authors:  David Fiorentino; Lorinda Chung; Jeff Zwerner; Antony Rosen; Livia Casciola-Rosen
Journal:  J Am Acad Dermatol       Date:  2011-04-29       Impact factor: 11.527

7.  Pseudovitiligo in Systemic Sclerosis.

Authors:  Vandana Mehta Rai; C Balachandran
Journal:  Dermatol Online J       Date:  2005-12-01

8.  Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension.

Authors:  Ami A Shah; Fredrick M Wigley; Laura K Hummers
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

Review 9.  The many faces of scleroderma.

Authors:  Virginia D Steen
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

10.  Salt-and-pepper Appearance: A Cutaneous Clue for the Diagnosis of Systemic Sclerosis.

Authors:  Ashish Singh; S Ambujam; Asha Varghese; S P Vishranth; Neenu Sadanandan
Journal:  Indian J Dermatol       Date:  2012-09       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.